Is It Too Late To Consider Phibro Animal Health (PAHC) After Its 235% One-Year Surge?

• If you are wondering whether Phibro Animal Health’s share price still makes sense after a big run, this article walks through what that current price might imply about value.
• The stock last closed at US$57.89, with returns of 4.3% over 7 days, 17.0% over 30 days, 55.2% year to date and 235.2% over the past year.
• Recent coverage has focused on Phibro Animal Health as part of broader discussions around animal health companies and how investors are reassessing risks and business models in this space. That context helps frame why the stock’s performance has been on many radars, even outside specialist healthcare circles.
• Despite that attention, the company currently holds a valuation score of 2 out of 6. The next sections look at what different valuation methods say about this price and finish with a way to think about valuation that goes beyond just the numbers.

Phibro Animal Health scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Phibro Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Phibro Animal Health is expected to generate in the future and then discounts those cash flows back to today to estimate what the business may be worth now.

Phibro Animal Health most recently reported Free Cash Flow of about $42.3 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to Free Cash Flow reaching $246.9 million in 2035, with interim years such as 2026 and 2028 projected at $95.7 million and $135.7 million respectively. All of these cash flows are in US$ and are discounted back using the DCF framework set out by Simply Wall St.

On this basis, the model estimates an intrinsic value of roughly $119.16 per share. Compared with the latest share price of $57.89, this implies the stock is around 51.4% undervalued using these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Phibro Animal Health is undervalued by 51.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Phibro Animal Health.

Approach 2: Phibro Animal Health Price vs Earnings

For a profitable business, the P/E ratio is a simple way to see what investors are currently paying for each dollar of earnings. It connects directly to the bottom line, which is usually the main driver of long term shareholder returns.

In general, higher growth expectations and lower perceived risk can justify a higher P/E ratio, while slower growth or higher risk tend to support a lower, more conservative P/E. So the question is what looks like a reasonable or “normal” P/E for Phibro Animal Health today.

Phibro Animal Health currently trades on a P/E of 25.48x. That sits above the Pharmaceuticals industry average of 16.97x and the broader peer average of 11.59x. Simply Wall St also calculates a proprietary “Fair Ratio” for the company of 17.36x, which reflects factors such as earnings growth, profit margins, industry, market cap and specific risks.

This Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for company specific characteristics rather than assuming all firms deserve the same multiple.

Comparing the current 25.48x P/E with the Fair Ratio of 17.36x suggests the shares are trading above what this framework views as a balanced level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Phibro Animal Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Phibro Animal Health, link it to a concrete forecast for revenue, earnings and margins, and turn that into a Fair Value that you can compare with the current price.

On Simply Wall St’s Community page, Narratives are an accessible tool that lets you set out your view in plain language, connect it to the numbers you think are reasonable, and then see what price those assumptions line up with.

Because Narratives are updated when new information such as earnings guidance or news is added to the platform, your Fair Value view adjusts automatically rather than sitting frozen in an old spreadsheet.

For example, one Phibro Animal Health Narrative on the cautious side might anchor around a Fair Value of US$38.0, while a more optimistic Narrative might point to US$58.0. By seeing both together you can decide which story and Fair Value range feel closer to your own expectations before comparing them with the current share price.

For Phibro Animal Health, here are previews of two leading Phibro Animal Health Narratives to make comparison easier:

🐂 Phibro Animal Health Bull Case

Fair Value: US$58.00

Implied discount to this Fair Value versus the last close of US$57.89: around 0.2% undervalued.

Revenue growth assumption used in this narrative: 3.9%.

• Assumes revenue reaches about US$1.6b and earnings of US$154.7m by 2029, with profit margins rising from 6.3% to 9.4%.
• Sees Phibro Forward and international expansion, particularly in Asia and Latin America, as key supports for higher and more stable earnings.
• Recognises risks from reliance on medicated feed additives, regulation, and costs, and uses a 7.0% discount rate and 18.6x future P/E to connect those assumptions to a US$58.00 Fair Value.

🐻 Phibro Animal Health Bear Case

Fair Value: US$48.50

Implied premium to this Fair Value versus the last close of US$57.89: around 19.4% overvalued.

Revenue growth assumption used in this narrative: 3.5%.

• Works off analyst assumptions that revenue reaches about US$1.5b and earnings of US$119.1m by 2028, with margins stepping up from 3.7% to 7.7%.
• Flags that a 14.6x future P/E, below the current US Pharmaceuticals industry level cited in the narrative, is needed to justify the US$35.75 consensus target.
• Highlights concerns that integration benefits and higher margin segments may normalise while regulation, environmental policy, and changing protein demand could pressure long term growth and profitability.

Put side by side, these Narratives frame a Fair Value range of roughly US$48.50 to US$58.00 around the current US$57.89 share price. This gives you a clear sense of what different earnings, margin, and P/E assumptions would need to be true for each story to hold.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Phibro Animal Health on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Do you think there’s more to the story for Phibro Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com